Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals.
نویسندگان
چکیده
available at: http://www.ncbi.nlm.nih.gov/pubmed/12606142. Accessed September 25, 2009. 7. Baker LC, Atlas SW, Afendulis CC. Expanded use of imaging technology and the challenge of measuring value. Health Aff. (Millwood). 2008;27(6):1467-478. 8. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207. Available at: http://content.nejm.org/cgi/ reprint/359/21/2195.pdf. Accessed September 25, 2009. 9. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 129: Bortezomib monotherapy for relapsed multiple myeloma. 2007. Available at http://guidance.nice.org.uk/TA129. Accessed
منابع مشابه
مقایسه نظام قیمت گذاری و بیمه دارو در ایران و کشورهای منتخب
Introduction: Pharmaceuticals comprise a large portion of health care expenditures, including insurance organizations expenditures. Accumulated evidence suggests that the inefficiencies of Iran's health insurance structure have led to soaring out- of- pocket payments by the beneficiaries of health insurance organizations. This study was conducted to compare pricing and reimbursement of pharmace...
متن کاملLinking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.
OBJECTIVE To identify, categorize and examine performance-based health outcomes reimbursement schemes for medical technology. METHODS We performed a review of performance-based health outcomes reimbursement schemes over the past 10 years (7/98-010/09) using publicly available databases, web and grey literature searches, and input from healthcare reimbursement experts. We developed a taxonomy ...
متن کاملPaying for On-Patent Pharmaceuticals
In this article we propose a new approach to pricing for patent-protected (on-patent) pharmaceuticals. We describe and define limit pricing as a method for drug companies to maximize revenue for their investment by offering budget-neutral pricing to encourage early adoption by payers. Under this approach, payers are incentivized to adopt innovative but expensive drugs more quickly if drug compa...
متن کاملPolicy Choices for Progressive Realization of Universal Health Coverage; Comment on “Ethical Perspective: Five Unacceptable Trade-offs on the Path to Universal Health Coverage”
In responses to Norheim’s editorial, this commentary offers reflections from Thailand, how the five unacceptable trade-offs were applied to the universal health coverage (UHC) reforms between 1975 and 2002 when the whole 64 million people were covered by one of the three public health insurance systems. This commentary aims to generate global discussions on how best UHC can be gradually achieve...
متن کاملPrioritising, Ranking and Resource Implementation - A Normative Analysis
Background Priority setting in publicly financed healthcare systems should be guided by ethical norms and other considerations viewed as socially valuable, and we find several different approaches for how such norms and considerations guide priorities in healthcare decision-making. Common to many of these approaches is that interventions are ranked in relation to each other, following the appli...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Journal of managed care pharmacy : JMCP
دوره 15 8 شماره
صفحات -
تاریخ انتشار 2009